The effects of the therapy in a small group of patients were long-lasting, researchers say, adding to evidence that the approach works for treatment-resistant depression.

Get sample PDF Brochure Here https://bit.ly/2zSTcQu

Deep brain stimulation, or DBS, involves implanting a small neurostimulator into a patient’s brain to send out electrical impulses to specific brain regions. The approach is approved by the US Food and Drug Administration to treat epilepsy and Parkinson’s disease, among other conditions, but has long been controversial in depression treatment due to mixed findings of the treatment’s effectiveness in the last couple decades.

The current study evaluated the mental health of people who had been fitted with the implants during the previous eight years. “Most patients experienced a robust and sustained antidepressant response” to the therapy, the authors write in their paper. About one-third of the participants experienced a full remission of symptoms, while half reported a reduction. The team also found no adverse health effects of the device itself, although the surgical procedure to implant it was associated with common surgical complications such as infection in some patients.

The increasing demand for deep brain stimulation device depends on the increasing aging population and rising incidences of neurosurgical disorders. Additionally, the technological advancements improving the DBS devices and increasing demand for minimally invasive procedures likely to add novel opportunities for the global deep brain stimulation devices market in the forecast period.

Symptoms

Each disease type has a variety of symptoms that patients may experience. Common ones are:

Dystonia

Involuntary muscle contractions occurring during specific actions (e.g. writing)

Muscle contractions worsen with stress, fatigue or anxiety

Epilepsy

Temporary confusion

A staring spell

Loss of consciousness

Uncontrollable jerking movements of arms or legs

Emotional responses such as fear, anxiety or déjà vu

Parkinson’s Disease

Tremor

Bradykinesia – slowing down of movement

Stiffness

Abnormal walking

Source: The Insight Partners & aans.org

A treatment in the first few minutes of a stroke can lower the risk of death. The standard procedures to detect strokes provide only 40 to 80 percent of accuracy. However, a new device worn like a visor can detect strokes within seconds with an accuracy of more than 90 percent. In addition, the device can help transfer the patients with large vessel occlusion directly to hospitals with endovascular capabilities, routing around the less-equipped facilities and saving valuable time. The device operates on low-level radio waves through brain and records the waves passing through the fluids of brain. When someone is experiencing a stroke, the brain’s fluids undergo some changes, which produce irregularities in the brain pattern. The device records such asymmetries to detect the symptoms of strokes and take necessary actions accordingly.

Get sample PDF copy at: https://bit.ly/2zgOWK5

It is essential to speed up the post-stroke recovery process. A device is developed that can send data directly to doctors and help closely monitor stroke patients. Lizzy McAninch, a patient with an experience of stroke explained in an interview with BBC news, “The device is equipped with sensors that evaluates properly working muscles of post-stroke patients. Furthermore, it pinpoints the areas affected by the attack, and targets therapies to improve health.”

The device looks like small sticking plasters, which are easy to wear and can be used for a long time. The sensors send data even after patients are finished with their therapies and exercises. The data provide doctors a reliable source of information and helps them decide course of action for improvement of a patient. The manufacturers believe that the main challenge was to bind multiple sensors together on a small platform, so that patients feel comfortable to wear it during their exercises. Along with numerous advanced sensors, the prototype embeds a computing unit, power supplies, and Wi-Fi, which can give a real-time feedback to doctors about a patient’s health.

Numerous startups have developed tools to speed up the thrombectomy procedures. A Rochester-based startup has invented a new device to improve the treatment of ischemic strokes. The device provides surgeons a free movement around the desired areas and allows an effective delivery in thrombectomy surgeries. For now, developers are testing the prototype and hoping for its market availability by the end of summer. In addition, healthcare companies are now interested to use artificial intelligence (AI) to scan hundreds of National Health Service (NHS) stroke patients in a year. The increased number of stroke patients has forced doctors to analyze their scans faster and more accurately than ever. As a result, in several cases, experts came up with different conclusions after reading a same scan multiple times. This confusion can be solved with the help of AI.

Chris Mansi, the Founder and CEO of Viz.ai has been developing algorithms to save brain cells of stroke patients. The product is designed to analyze CT scans of stroke patients automatically. It uses an algorithm to spot blockages in brain blood vessels. Whenever, AI thinks it has found a blockage, it sends an alert to specialists and ask for their opinion. Furthermore, the software remembers specific images it finds important. Mansi explained, “The AI is not cutting anyone’s job out, however, this helps create a parallel workflow that can detect brain attack. As a lot of patients are not getting a faster treatment, AI-based technology has opened new gates in healthcare sector.”

The use of advanced technologies to detect stroke and the involvement of AI have boosted the stroke management market. In its recent report on the global stroke management market, The insight Partners outlines competitive situations and trends, provides insights sales, revenue, market share of key segments, and explores leading manufacturers. Furthermore, the report is helpful for market players, investors, and entry-level companies to understand the market conditions and take necessary steps to devise strategies for the future.

Source: The Insight Partners

Advances in management of motor symptoms of Parkinson’s disease (PD) have been seen in recent years in both medical management and surgical management. However, both PD patients and their physicians may not be familiar with the increasing options and therefore may not be taking advantage of available treatments.

Get PDF Brochure at: https://bit.ly/2RTBoKZ

Latest developments in Parkinson’s disease treatment, for instance, combination treatments to prolong the action of unremitting dopaminergic stimulation medicines, support for neurostimulation tools, neuroprotective treatment to slow down prediction of a disease, neural transplantation and gene therapy, and so on, are anticipated to bring huge development in global Parkinson’s disease treatment market in the coming future. In addition, growing aging inhabitants, the occurrence of Parkinsonism across the globe are the major aspects propelling the demand and requirement for the global Parkinson’s disease treatment market. Also, increasing old age inhabitants and higher occurrences of the neurodegenerative syndrome are two important aspects that are likely to fuel the development of the global Parkinson’s disease treatment market. In addition, growing R&D venture and a number of medicines in the pipeline are further projected to propel the market development. On the other hand, high expenditure of treatment and short of proficiency for early diagnosis is anticipated to curtail the market development.

Some of the most important market players in the Parkinson’s disease treatment market are Salix Pharmaceuticals, GlaxoSmithKline Plc., Teva Pharmaceutical Industries Ltd., Impax Laboratories, Inc., Orion Corporation, Novartis AG, Par Pharmaceutical, Mylan N.V., Daiichi Sankyo, Cipla Inc., Wockhardt Limited, and Apotex Inc., among others.

The global Parkinson’s disease treatment market is fragmented in terms of drug type and geography. On the basis of drug type, the market is classified into, pipeline and marketed drugs. The marketed drugs division are further categorized into Dopamine agonists, Levodopa, Glutamate antagonist, Apomorphine, COMT inhibitors Anticholinergics, and MAO-B inhibitors.

Source: The Insight Partners

According to the data published by WHO, there are around 50 million cases of dementia across the globe amongst which 60–70% is Alzheimer’s and 10 million are added every year. Dementia is the fifth leading cause of death worldwide. Furthermore, the incidence rate for Parkinson’s disease is 4.5–19 per 100,000 population every year.

Download PDF Brochure at: https://bit.ly/2ymgxJG

Chronic pain is the most common problem faced by millions across the world and at the same time is left untreated in most of the cases. Lower back pain, migraine, stroke, traumatic brain injury, epilepsy, spinal cord injury, and multiple sclerosis are the most prevalent neurological disorders. Approximately 3.97 billion people were diagnosed with chronic pain and neurological disorders, in the U.S., in 2017.

These growing incidences of neurological disorders are resulting in loss of work productivity and are further contributing to the global economic burden. Additionally, prolonged chronic pain also increases the risk of disability, depression, and anxiety. Performing everyday activities such as cleaning, bathing, and fitness and sports activities also becomes a challenge for people with chronic pain.

Opioids, a type of narcotic pain medication, have gained much traction owing to the increasing number of chronic pain cases. Opioids are very powerful drugs and may seem the ideal medicine for treating chronic pain. However, a long list of side-effects and the risk of addiction is associated with their use. The abuse of opioids has led to stringent governmental regulations imposed on their use and sale.

This has shifted the focus of the medical industry toward the neuromodulation technologies for the treatment of chronic pain and neurological disorders. Neurostimulation devices are being manufactured and adopted across the globe at a robust rate, owing to their specific, efficient, and safe approach to treat such diseases.

Source: The Insight Partners